Clinical trials testing iPSC-derived NK and T cells
| Trial # . | Phase . | Product . | Disease settings . | Stage . |
|---|---|---|---|---|
| NCT03841110 | 1 | Nontransduced iPSC-derived NK cells (FT500) with checkpoint blockade | Advanced solid tumors | Active, not recruiting |
| NCT04363346 | 1 | FT516 (hnCD16) iPSC-derived NK cells | COVID-19 | Completed |
| NCT04023071 | 1 | FT516 (hnCD16) iPSC-derived NK cells with obinutuzumab | AML, B-cell lymphoma | Recruiting |
| NCT04630769 | 1 | FT516 (hnCD16) iPSC-derived NK cells with enoblituzumab and IL-2 | Ovarian cancer | Completed |
| NCT04551885 | 1 | FT516 (hnCD16) iPSC-derived NK cells with avelumab | Advanced solid tumors | Active, not recruiting |
| NCT04714372 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab | AML | Recruiting |
| NCT05069935 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with monoclonal antibodies | Advanced solid tumors | Recruiting |
| NCT04614636 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab or elotuzumab | AML, multiple myeloma | Recruiting |
| NCT04555811 | 1 | FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab | NHL, diffuse large B-cell lymphoma, high-grade B-cell lymphoma | Recruiting |
| NCT04245722 | 1 | FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab or obinutuzumab | B-cell lymphoma, CLL | Recruiting |
| NCT05395052 | 1 | FT536 (hnCD16/CD38KO/anti-MICA/B CAR/IL-15RF) iPSC-derived NK cells with monoclonal antibodies | Advanced solid tumors | Recruiting |
| NCT05182073 | 1 | FT576 (IL-15RF/CD38KO/anti-BCMA CAR) iPSC-derived NK cells with daratumumab | Multiple myeloma | Recruiting |
| NCT05336409 | 1 | CNTY-101 (sIL-15/EGFRt/anti-CD19 CAR) iPSC-derived T cells with IL-2 | CD19+ B-cell malignancies NHL | Not yet recruiting |
| NCT04629729 | 1 | FT819 (CD8αβ anti-CD19 CAR) iPSC-derived T cells with IL-2 | Lymphoma, CLL, precursor B-cell ALL | Recruiting |
| Trial # . | Phase . | Product . | Disease settings . | Stage . |
|---|---|---|---|---|
| NCT03841110 | 1 | Nontransduced iPSC-derived NK cells (FT500) with checkpoint blockade | Advanced solid tumors | Active, not recruiting |
| NCT04363346 | 1 | FT516 (hnCD16) iPSC-derived NK cells | COVID-19 | Completed |
| NCT04023071 | 1 | FT516 (hnCD16) iPSC-derived NK cells with obinutuzumab | AML, B-cell lymphoma | Recruiting |
| NCT04630769 | 1 | FT516 (hnCD16) iPSC-derived NK cells with enoblituzumab and IL-2 | Ovarian cancer | Completed |
| NCT04551885 | 1 | FT516 (hnCD16) iPSC-derived NK cells with avelumab | Advanced solid tumors | Active, not recruiting |
| NCT04714372 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab | AML | Recruiting |
| NCT05069935 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with monoclonal antibodies | Advanced solid tumors | Recruiting |
| NCT04614636 | 1 | FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab or elotuzumab | AML, multiple myeloma | Recruiting |
| NCT04555811 | 1 | FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab | NHL, diffuse large B-cell lymphoma, high-grade B-cell lymphoma | Recruiting |
| NCT04245722 | 1 | FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab or obinutuzumab | B-cell lymphoma, CLL | Recruiting |
| NCT05395052 | 1 | FT536 (hnCD16/CD38KO/anti-MICA/B CAR/IL-15RF) iPSC-derived NK cells with monoclonal antibodies | Advanced solid tumors | Recruiting |
| NCT05182073 | 1 | FT576 (IL-15RF/CD38KO/anti-BCMA CAR) iPSC-derived NK cells with daratumumab | Multiple myeloma | Recruiting |
| NCT05336409 | 1 | CNTY-101 (sIL-15/EGFRt/anti-CD19 CAR) iPSC-derived T cells with IL-2 | CD19+ B-cell malignancies NHL | Not yet recruiting |
| NCT04629729 | 1 | FT819 (CD8αβ anti-CD19 CAR) iPSC-derived T cells with IL-2 | Lymphoma, CLL, precursor B-cell ALL | Recruiting |
ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma.